- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06283563
Online Physical Activity Tracking in Patients With Multiple Sclerosis
February 21, 2024 updated by: Burcu Talu, Inonu University
The Effect of Online Physical Activity Tracking on Physical Activity Level, Psychological Health, Fatigue and Quality of Life in Patients With Multiple Sclerosis
This study aims to investigate the effects of regular remote monitoring of physical activity levels of individuals with multiple sclerosis on physical activity levels, psychological health, fatigue and quality of life.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The study population will consist of patients with multiple sclerosis.
Participants in the intervention and control groups will initially be given a brief briefing about the benefits of exercise training.
Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given.
Participants in the intervention group will be allowed to join the group created by the researchers via Whatsapp.
In this regard, it will be emphasized that should exercise at least 3 days a week.
The participant will be asked to fill out the survey created via Google form in order to record their activity minutes in these three days.
The total intervention period will be 8 weeks.
Reminders to exercise will be given by the researchers in the created Whatsapp group.
Participants in the control group will be encouraged to continue their routine lives.
Average step counts will be recorded before and after treatment.
Additionally, they will be asked to report their average step count each week via WhatsApp groups.
Pre- and post-intervention evaluations will be carried out by a physiotherapist.
Patients' physical activity levels, depression and anxiety, fatigue and quality of life parameters will be examined.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Busra CANDIRI
- Phone Number: +9005073780717
- Email: candiri_17@hotmail.com
Study Contact Backup
- Name: dilan demirtas karaoba
- Email: dilandemirtas92@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
->18 years old
- Being diagnosed with multiple sclerosis according to McDonald's diagnostic criteria, owning a smartphone and using the WhatsApp application,
- Having regular internet access
- Not participating in a regular physical activity program in the last 6 months,
- Expanded Disability Status Scale<6
Exclusion Criteria:
- Having an attack during work,
- Any orthopedic or neurological disorder that affects compliance with the physical activity program,
- Not having independent mobility ability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group
Participants will receive reminders regarding physical activity promotion via the social media group created.
|
At the beginning, patients will be given a brief information about the benefits of exercise training.
Additionally, a short brochure explaining the effects of exercise in MS will be given.
Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app.
Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group.
In this regard, it will be emphasized that he/she should exercise at least 3 days a week.
In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine.
The total intervention period will be 8 weeks.
Reminders to exercise will be given by the researchers in the created messaging app group.
Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
|
|
Active Comparator: Control group
Participants will be encouraged to continue their routine lives.
|
At the beginning, patients will be given a brief information about the benefits of exercise training.
Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given.
Participants will be encouraged to continue their routine lives and no reminders will be given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smartphone pedometer
Time Frame: Baseline
|
The number of steps in the pedometer application of the current smartphone on the individual's phone will be recorded.
|
Baseline
|
|
Smartphone pedometer
Time Frame: 8 week
|
The number of steps in the pedometer application of the current smartphone on the individual's phone will be recorded.
|
8 week
|
|
International Physical Activity Questionnaire - Short Form
Time Frame: Baseline
|
It consists of 8 questions with a recall period defined as 'last week'.
The questions of the scale ask whether the participant walks for at least 10 minutes on any given day or does moderate or vigorous activities, and how much time/day the individual spends on each of these activities.
|
Baseline
|
|
International Physical Activity Questionnaire - Short Form
Time Frame: 8 week
|
It consists of 8 questions with a recall period defined as 'last week'.
The questions of the scale ask whether the participant walks for at least 10 minutes on any given day or does moderate or vigorous activities, and how much time/day the individual spends on each of these activities.
|
8 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory II
Time Frame: Baseline
|
Inventory consists of 21 items, in which four response options are presented on a scale of 0 to 3. For example, to measure pessimism (item 2) the response options used range from "I am not particularly discouraged about the future" (score of 0) to "the future is hopeless and things cannot improve" (score of 3).
|
Baseline
|
|
Beck Depression Inventory II
Time Frame: 8 week
|
Inventory consists of 21 items, in which four response options are presented on a scale of 0 to 3. For example, to measure pessimism (item 2) the response options used range from "I am not particularly discouraged about the future" (score of 0) to "the future is hopeless and things cannot improve" (score of 3).
|
8 week
|
|
Beck Anxiety Inventory
Time Frame: Baseline
|
The Beck Anxiety Inventory consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms during the past week.
Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).
|
Baseline
|
|
Beck Anxiety Inventory
Time Frame: 8 week
|
The Beck Anxiety Inventory consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms during the past week.
Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).
|
8 week
|
|
Fatigue Severity Scale
Time Frame: Baseline
|
The classification is <36 mild no fatigue, 36-52 = moderate fatigue and >52 severe fatigue
|
Baseline
|
|
Fatigue Severity Scale
Time Frame: 8 week
|
The classification is <36 mild no fatigue, 36-52 = moderate fatigue and >52 severe fatigue
|
8 week
|
|
Multiple Sclerosis Quality of Life-54
Time Frame: Baseline
|
It is a multidimensional, health-related quality of life measure that combines both general and MS-specific items into a single instrument.
It consists of a total of 54 items.
Patients will be considered to have a better quality of life as they get closer to 100 on a 0-100 rating system.
|
Baseline
|
|
Multiple Sclerosis Quality of Life-54
Time Frame: 8 week
|
It is a multidimensional, health-related quality of life measure that combines both general and MS-specific items into a single instrument.
It consists of a total of 54 items.
Patients will be considered to have a better quality of life as they get closer to 100 on a 0-100 rating system.
|
8 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Burcu talu, İnonu University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 28, 2024
Primary Completion (Estimated)
February 15, 2025
Study Completion (Estimated)
February 28, 2025
Study Registration Dates
First Submitted
February 21, 2024
First Submitted That Met QC Criteria
February 21, 2024
First Posted (Actual)
February 28, 2024
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/5474
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Study data can be shared with other researchers if desired.
IPD Sharing Time Frame
After the study was published
IPD Sharing Access Criteria
If requested from the authors, it can be shared with researchers at the authors' discretion.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Physical activity tracking
-
University of VictoriaRecruiting
-
Dr Falk Mueller-RiemenschneiderUnknown
-
Technische Universität DresdenCompletedLiver Resection | Colorectal Resection | Pancreatic Resection | Gastric ResectionGermany
-
University of TromsoUniversity Hospital of North NorwayNot yet recruitingFibromyalgia | Fibromyalgia Syndrome | Fibromyalgia (FM)Norway
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
University of NottinghamBiotechnology and Biological Sciences Research CouncilRecruitingMetabolic Syndrome | Sedentary Behavior | Age-related Cognitive Decline | Age-Related SarcopeniaUnited Kingdom